PL2981272T3 - Mikroporowaty krzemian cyrkonu i diuretyki do redukcji potasu i leczenia przewlekłych chorób nerek i/lub przewlekłych chorób serca - Google Patents

Mikroporowaty krzemian cyrkonu i diuretyki do redukcji potasu i leczenia przewlekłych chorób nerek i/lub przewlekłych chorób serca

Info

Publication number
PL2981272T3
PL2981272T3 PL14779186.7T PL14779186T PL2981272T3 PL 2981272 T3 PL2981272 T3 PL 2981272T3 PL 14779186 T PL14779186 T PL 14779186T PL 2981272 T3 PL2981272 T3 PL 2981272T3
Authority
PL
Poland
Prior art keywords
chronic
diuretics
potassium
reduction
treatment
Prior art date
Application number
PL14779186.7T
Other languages
English (en)
Polish (pl)
Inventor
Donald Jeffrey Keyser
Alvaro F. Guillem
Original Assignee
Zs Pharma, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51654632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2981272(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zs Pharma, Inc filed Critical Zs Pharma, Inc
Publication of PL2981272T3 publication Critical patent/PL2981272T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14779186.7T 2013-04-05 2014-04-03 Mikroporowaty krzemian cyrkonu i diuretyki do redukcji potasu i leczenia przewlekłych chorób nerek i/lub przewlekłych chorób serca PL2981272T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361808897P 2013-04-05 2013-04-05
US201361914362P 2013-12-10 2013-12-10
US201461930331P 2014-01-22 2014-01-22
PCT/US2014/032815 WO2014165670A1 (en) 2013-04-05 2014-04-03 Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

Publications (1)

Publication Number Publication Date
PL2981272T3 true PL2981272T3 (pl) 2023-05-29

Family

ID=51654632

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14779186.7T PL2981272T3 (pl) 2013-04-05 2014-04-03 Mikroporowaty krzemian cyrkonu i diuretyki do redukcji potasu i leczenia przewlekłych chorób nerek i/lub przewlekłych chorób serca

Country Status (21)

Country Link
US (3) US20140302175A1 (enExample)
EP (1) EP2981272B1 (enExample)
JP (1) JP6280636B2 (enExample)
KR (1) KR102308673B1 (enExample)
CN (1) CN105473151B (enExample)
AU (1) AU2014248081B2 (enExample)
BR (1) BR112015025438B1 (enExample)
CA (1) CA2908641C (enExample)
CL (1) CL2015002951A1 (enExample)
DK (1) DK2981272T3 (enExample)
ES (1) ES2943007T3 (enExample)
FI (1) FI2981272T3 (enExample)
HU (1) HUE061862T2 (enExample)
IL (1) IL241926B (enExample)
MX (1) MX2015014055A (enExample)
PH (1) PH12015502301A1 (enExample)
PL (1) PL2981272T3 (enExample)
PT (1) PT2981272T (enExample)
TW (1) TW201521746A (enExample)
WO (1) WO2014165670A1 (enExample)
ZA (1) ZA201507666B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900037T1 (it) 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
CN114917247B (zh) * 2022-05-18 2024-01-26 广东省疾病预防控制中心 纳米二氧化钛在防治肾损伤中的应用
CN117776193A (zh) * 2023-12-25 2024-03-29 杭州国瑞生物科技有限公司 一种环硅酸锆钠zs-9的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601398D0 (en) * 1996-01-24 1996-03-27 Piper Edwina M Composition
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
EP1307270A1 (en) * 2000-07-12 2003-05-07 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
AU2002242103A1 (en) * 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) * 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
CN103919792B (zh) 2008-08-22 2018-03-09 瑞立普萨公司 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
SMT201900037T1 (it) * 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
MX2015000381A (es) * 2012-07-11 2015-11-23 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
KR102184602B1 (ko) * 2012-10-22 2020-11-30 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트

Also Published As

Publication number Publication date
JP6280636B2 (ja) 2018-02-14
CA2908641C (en) 2022-10-18
EP2981272A1 (en) 2016-02-10
IL241926B (en) 2020-10-29
AU2014248081B2 (en) 2019-02-28
MX2015014055A (es) 2015-12-15
CL2015002951A1 (es) 2016-11-11
FI2981272T3 (fi) 2023-05-03
HUE061862T2 (hu) 2023-08-28
EP2981272A4 (en) 2016-12-07
WO2014165670A1 (en) 2014-10-09
EP2981272B1 (en) 2023-03-01
KR20150140750A (ko) 2015-12-16
US20140302175A1 (en) 2014-10-09
CN105473151B (zh) 2018-09-18
DK2981272T3 (da) 2023-05-01
US10695366B2 (en) 2020-06-30
BR112015025438B1 (pt) 2022-06-07
JP2016515624A (ja) 2016-05-30
HK1221177A1 (en) 2017-05-26
AU2014248081A1 (en) 2015-11-12
PH12015502301A1 (en) 2016-02-10
US20180271902A1 (en) 2018-09-27
ES2943007T3 (es) 2023-06-08
KR102308673B1 (ko) 2021-10-01
CN105473151A (zh) 2016-04-06
CA2908641A1 (en) 2014-10-09
ZA201507666B (en) 2019-09-25
PT2981272T (pt) 2023-05-03
BR112015025438A2 (pt) 2017-07-18
TW201521746A (zh) 2015-06-16
US20160051584A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
PL2943493T3 (pl) Związki terapeutyczne do leczenia zakażeń wirusowych
IL240765A0 (en) Macrocyclic daza-furanones for the treatment of viral infections
PT3019503T (pt) Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
SI3019499T1 (sl) Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij
SMT202200314T1 (it) Uso di solfati di colesterolo ossigenati (ocs) per il trattamento di disfunzione epatica
DK3730136T3 (da) Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
ZA201601351B (en) Organophosphates for treating afflictions of the skin
ZA201603171B (en) Microporous zirconium silicate for the treatment of hyperkalemia
IL245525A0 (en) Microporous zirconium silicate for the treatment of hyperkalemia
HUE063776T2 (hu) Dulaglutid krónikus vesebetegség kezelésére
ZA201507666B (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei
IL311363A (en) Compositions for use in treating cognitive impairment
GB201317564D0 (en) Therapeutic for the treatment of Lung Cancer
GB201321628D0 (en) Treatment of disease